You need to be logged in to view this video
John McCamant has spent 35 years on the front lines of biotech investing as an equities analyst and in venture capital. He has also edited the Medical Technology Stock Letter since the year 2000. In this session, he'll tell you about the methodology he uses to sift through hundreds of biotech companies to find the best in class drugs like MDGL for long-term growth. Plus, John will highlight the most attractive biotech opportunities in this premier growth sector for the rest of 2023 and beyond.
John McCamant
Medical Technology Stock Letter,
Editor
John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
Trending Now
Filter By Category
Filter By Keywords
Loading...